Refanezumab

DB14908Investigational

Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).

Mechanism: Pharmacologically active on Myelin-associated glycoprotein
Curator reviewed
Code names: GSK249320

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Refanezumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.